Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 13/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20775957 | 0.84 | KMT2A (0.67) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22424928 | 0.84 | MAPT (0.76) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL6740302 | 0.83 | MEN1 (0.69) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22425088 | 0.83 | ALDH1A1 (0.76) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22424899 | 0.82 | MAPT (0.68) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL20777328 | 0.82 | MAPT (0.75) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22424896 | 0.81 | MAPT (0.66) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22424884 | 0.81 | MAPT (0.62) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22425073 | 0.81 | MAPT (0.66) | KDM4EGAAMAPTKMT2AMEN1 | |
| SCHEMBL22425346 | 0.81 | MAPT (0.76) | KDM4EGAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | RB1, CNKSR1, RBBP4 | KDM4E 1092/4885GAA 3349/4885MAPT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.